KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Operating Leases (2019 - 2025)

Twist Bioscience (TWST) has disclosed Operating Leases for 7 consecutive years, with $85.8 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 26.96% to $85.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85.8 million through Dec 2025, up 26.96% year-over-year, with the annual reading at $61.8 million for FY2025, 12.06% down from the prior year.
  • Operating Leases for Q4 2025 was $85.8 million at Twist Bioscience, up from $61.8 million in the prior quarter.
  • The five-year high for Operating Leases was $91.9 million in Q4 2023, with the low at $22.2 million in Q1 2021.
  • Average Operating Leases over 5 years is $69.9 million, with a median of $71.4 million recorded in 2024.
  • The sharpest move saw Operating Leases tumbled 34.99% in 2021, then skyrocketed 258.13% in 2022.
  • Over 5 years, Operating Leases stood at $60.3 million in 2021, then surged by 32.28% to $79.7 million in 2022, then grew by 15.21% to $91.9 million in 2023, then decreased by 26.44% to $67.6 million in 2024, then rose by 26.96% to $85.8 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $85.8 million, $61.8 million, and $62.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.